Key Points
- Director Brian Taylor Slingsby sold 1,000,000 shares of Mineralys on Nov. 20 at an average price of $43.35 (totaling $43.35M), trimming his position by 11.23% to 7,903,838 shares, as disclosed in an SEC filing.
- MLYS traded around $41.87 midday with a 52‑week range of $8.24–$47.65, a market cap of $3.31B and a negative P/E of -14.19 (50‑day/200‑day moving averages $40.70/$24.93).
- Analysts carry a consensus "Moderate Buy" with an average target of $46.67 and several firms (HC Wainwright, Goldman Sachs) raising price targets, while institutional investors own about 84.46% of the stock.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) Director Brian Taylor Slingsby sold 1,000,000 shares of Mineralys Therapeutics stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $43.35, for a total value of $43,350,000.00. Following the transaction, the director owned 7,903,838 shares in the company, valued at $342,631,377.30. This represents a 11.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Mineralys Therapeutics Stock Performance
Mineralys Therapeutics stock remained flat at $41.87 during mid-day trading on Friday. The company had a trading volume of 1,675,839 shares, compared to its average volume of 1,705,114. The stock's 50-day moving average is $40.70 and its 200 day moving average is $24.93. The firm has a market cap of $3.31 billion, a P/E ratio of -14.19 and a beta of 0.40. Mineralys Therapeutics, Inc. has a 1 year low of $8.24 and a 1 year high of $47.65.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Monday, November 10th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.14. As a group, equities analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Mineralys Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the business. Smartleaf Asset Management LLC boosted its holdings in Mineralys Therapeutics by 198.2% in the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company's stock worth $40,000 after purchasing an additional 676 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Mineralys Therapeutics by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company's stock valued at $271,000 after buying an additional 702 shares in the last quarter. AlphaQuest LLC lifted its position in shares of Mineralys Therapeutics by 4.6% in the first quarter. AlphaQuest LLC now owns 15,925 shares of the company's stock worth $253,000 after buying an additional 703 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Mineralys Therapeutics by 51.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company's stock worth $34,000 after acquiring an additional 850 shares in the last quarter. Finally, Velan Capital Investment Management LP increased its holdings in shares of Mineralys Therapeutics by 0.6% during the 3rd quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company's stock valued at $6,659,000 after acquiring an additional 1,000 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on the stock. HC Wainwright upped their price objective on shares of Mineralys Therapeutics from $52.00 to $56.00 and gave the company a "buy" rating in a research note on Wednesday, November 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Wednesday, October 8th. Wall Street Zen raised shares of Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, August 22nd. The Goldman Sachs Group lifted their price objective on Mineralys Therapeutics from $32.00 to $52.00 and gave the company a "buy" rating in a research report on Tuesday, September 9th. Finally, Jefferies Financial Group boosted their target price on Mineralys Therapeutics from $15.00 to $26.00 and gave the company a "hold" rating in a research note on Wednesday, September 3rd. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Mineralys Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $46.67.
Get Our Latest Research Report on MLYS
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
